Updated:
Eli Lilly and Company
Eli Lilly and Company: Dave Ricks runs the $800B+ pharmaceutical giant focused on Mounjaro, AI drug discovery, and global clinical trials.
Eli Lilly and Company
Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly in Indianapolis. The company remains headquartered there, led by CEO Dave Ricks since 2017. Wealth origin traces to pharmaceutical innovation, not a single family trust; the Lilly Endowment, a separate philanthropic entity, holds roughly 12% of shares. The firm's strategy focuses on discovering and commercializing drugs across oncology, immunology, neuroscience, and cardiometabolic diseases. Its blockbuster GLP-1 franchise Mounjaro for type 2 diabetes and Zepbound for obesity generated over $12B in combined 2024 sales (per SEC filings, 2025). Lilly invests heavily in AI-driven drug discovery, including a partnership with OpenAI and a $2.5B biologics manufacturing expansion in Indiana. The company operates clinical trials and sales in over 120 countries. Lilly employs roughly 43,000 people globally. Beyond Indianapolis, R&D hubs include San Diego and Shanghai. A 2024 operational event: In May 2024, Lilly announced a $5.3B acquisition of MorphiC, a biotech developing gene therapy tools, to expand its genetic medicine capabilities (per Lilly press release, May 2024). The Lilly Endowment, funded entirely by the company's stock, awards grants in religion, education, and community development without overlap with corporate R&D spending. Lilly's structural differentiator is its dual identity: a public pharmaceutical manufacturer with a foundation-linked ownership structure, not a family office. The Lilly Endowment, one of the largest U.S. philanthropies with over $15B in assets, provides long-term shareholder stability and insulates the company from activist pressure — a governance architecture rare among peer drugmakers.
General information
Firm type
Asset Manager
Year founded
1876
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Indianapolis
Corporate office
Indianapolis, IN, United States
Additional offices
San Diego · New York · Shanghai
Principals
Dave Ricks
Chair and CEO
Anat Ashkenazi
CFO (until 2024)
Luca Visinelli
EVP, International
Dan Skovronsky
EVP, Chief Scientific Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Eli Lilly?
CEO Dave Ricks and Chief Scientific Officer Dan Skovronsky set the R&D investment strategy, with board oversight. CFO Anat Ashkenazi departed in 2024; Lucinda Meyer now serves as interim CFO. Capital allocation decisions for acquisitions and R&D projects go through an internal executive committee.
How does Eli Lilly source proprietary drug candidates?
Lilly sources primarily through internal discovery labs in Indianapolis, San Diego, and Shanghai. It also licenses early-stage biotech molecules and executes bolt-on acquisitions like MorphiC in 2024. The company does not rely on external VC funds for deal flow.
Is Eli Lilly structured as a family office or a public company?
Eli Lilly is a publicly traded corporation on the NYSE under ticker LLY. The Lilly Endowment holds a significant minority stake, providing long-term orientation, but the firm operates as a traditional pharma company, not a family office.
Does Eli Lilly participate in fund commitments or only direct investments?
Lilly does not commit capital to external GP funds. All investment is direct into internal R&D programs, licensing deals, and M&A. It does not operate a venture capital arm, though it has made minority investments in companies like Sigilon Therapeutics.
What investment stages does Eli Lilly typically target?
Lilly invests across the drug development lifecycle: early-stage preclinical discovery through its labs, phase 1-3 clinical trials, and commercial-stage launches. Acquisitions focus on assets in phase 2 or later to de-risk pipeline additions.
Which sectors does Eli Lilly explicitly avoid?
Lilly does not invest in non-healthcare sectors like real estate, energy, or technology outside of health IT. It also generally avoids generic drugs and animal health after spinning off Elanco in 2018.
How is Eli Lilly related to the Lilly Endowment?
The Lilly Endowment is a separate charitable trust created by members of the Lilly family. It holds about 12% of Lilly's shares but has no operational control over the company. The endowment's grants do not fund Lilly's R&D; they focus on community, education, and religious causes.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: